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[57] ABSTRACT 
Pharmaceutical compositions comprise as the active ingre 
dient potent orally active, nonneurotoxic anticonvulsant 
compounds that are excitatory amino acid and NMDA/ 
sigma receptor antagonists and that are selected from the 
group consisting of those of the formulae: 
R3 
wherein R1 is 4-pyridyl or 3-pyridyl, R2 is hydrogen or 
methyl and R3 is 3,4»dich1oro, p- or m-chloro, p-bromo. 
p-?uoro, p-methyl, p-methoxy or hydrogen. The composi 
tions are administered to mammals in an amount to provide 
a dosage amount ranging from about 15 mg/kg to 200 
mgkg. 
22 Claims, 1 Drawing Sheet 
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AMINOALKYLPYRIDINE CONIPOUNDS 
WHICH ARE USEFUL AS 
ANITCONVULSANT DRUGS, EXCITATORY 
AMINO ACID INHIBITORS AND NMDA 
SIGMA RECEPTOR ANTAGONISTS 
FIELD OF THE INVENTION 
This invention relates to novel aminoalkylpyridines and 
their method of preparation. and more particularly relates to 
novel aminoalkylpyridines which are useful as excitatory 
amino acid inhibitors and as NMDA/0' (sigma) receptor 
antagonists and potent orally active antiepileptic pharma 
ceutical compositions. 
BACKGROUND ART 
Epilepsy is a leading neurological disorder. second only to 
stroke. One to four million Americans and twenty to forty 
million people world-wide suffer from some form of 
epilepsy. making it second only to stroke as the leading 
neurological disorder. Although standard therapy permits 
control of seizures in 80% of these patients, one-half million 
people in the U.S. have uncontrolled epilepsy. The number 
of drugs useful for the treatment of epilepsy is remarkably 
small. Fewer than 20 drugs are currently marketed in the 
U.S.. and of these. only ?ve or six are widely used. Complex 
partial epilepsy (also known as temporal lobe. psycomotor 
or limbic epilepsy). the most devastating form among adults, 
and estimated to account for an many as two-thirds of all 
cases, is refractory to drug treatment (Gummit. R. J., ‘The 
Epilepsy Handbook. The Practical Management of 
Seizures”. Raven Press. New York. 1983). It is becoming 
increasingly evident that signi?cant progress toward com 
plete control can be achieved only by an understanding of 
the mechanisms of the epilepsies themselves. which will 
provide the molecular basis for antiepileptic drug design and 
development. and new treatment strategies. Out of the 
twenty or so new drugs that are in clinical trial in the U.S., 
only a few have been developed based on the knowledge of 
epilepsy mechanisms (Dichter. M. A.. Epilepsia, 30, 
S3-Sl2, 1989). 
NMDA receptor overstimulation by high levels of the 
excitatory amino acid (EAA), L-glutamate, has been impli 
cated in epileptogenesis and epilepsy (Cavalheiro, et al., 
“Frontiers in Excitatory Amino Acid Research”, A. R. Liss, 
New York. 1988). Thus. development of agents that are 
EAA/NMDA antagonists may constitute novel and eifective 
therapies for the epilepsies. Although a number of excitatory 
amino acid (EAA) inhibitors have been discovered, many 
lack NMDA receptor speci?city and are too toxic for clinical 
studies (Porter. Epilepsia. 30. $29-34. 1989). Thus. the 
discovery of this invention of certain aminoalkylpyridines as 
a superior class of anticonvulsant agents in the Applicant’s 
laboratories is signi?cant. The aminoalkylpyridines of this 
invention are potent, orally active. nonneurotoxic NMDA 
antagonists that hold promise for commercial development 
as nontoxic. clinically useful antiepileptic drugs. They can 
provide the basis for the design of safer NMDA antagonists 
with increased potency and reduced toxicity for the man 
agement of epilepsy in humans. 
Certain aminoalkylpyridines are known to the art as 
described in U.S. Pat. Nos. 4.358.446. 3522.262. and 3,654, 
290. Aminoalkyl-3-pyridines are described in U.S. Pat. No. 
4,358,446 as intermediates in the preparation of certain 
N-acylarninoalkyl-3-pyridine derivatives that have activity 
as fungicides. U.S. Pat. Nos. 3.522.262 and 3.654290. 
describe aminoalkylpyridines as intermediates for prepara 
tion of certain indole derivatives which have antiallergic 
activity. 
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SUMMARY OF THE INVENTION 
It is accordingly one object of the present invention to 
provide novel aminoalkylpyridines and their method of 
preparation. 
It is a further object of the present invention to provide 
anticonvulsant agents which comprise aminoalkylpyridines. 
A further object of the present invention is to provide a 
method for the treatment of convulsive disorders by admin 
istration of an effective amount of the aminoalkylpyridines 
of this invention. 
A further object of the present invention is to provide 
compounds belonging to two series of aminoalkylpyridine 
structures and methods for their use in the treatment of 
neurological disorders such as epilepsy and stroke. 
A still further object of the present invention is to provide 
new aminoalkylpyridines that are inhibitors of the excitatory 
amino acid (EAA) neurotransmitter L-glutarnate. The ami 
noalkylpyridines of this invention produce a signi?cant 
inhibition of the presynaptic release of L-glutamate and also 
act as noncompetitive NMDA antagonists by selectively 
inhibiting the speci?c binding of the radioligand [3H]DT G 
(ditolylguanidine) to <5 (sigma) receptor sites on the 
N-methyl-D-aspartate (NMDA) receptor complex in the 
brain. 
A still further object of the present invention is to provide 
anticonvulsant compositions which are highly active by the 
oral route and contain as the essential ingredient certain 
aminoalkylpyridines and use of these aminoalkylpyridines 
as potent orally active nonneurotoxic antiepileptic drugs in 
the treatment of convulsive disorders such as epilepsy. 
Other objects and advantages of the present invention 
include use of the aminoalkylpyridines in the treatment of 
stroke and other neurological disorders such as Alzheimer’s 
disease. by virtue of their action as noncompetitive NMDA 
antagonists and as inhibitors of the excitatory neurotrans 
mitter L-glutamate. 
In satisfaction of the foregoing objects and advantages. 
there are provided by this invention aminoalkylpyridine 
compounds which are useful as anticonvulsant drugs. These 
compounds may be characterized by the following general 
formulae: 
wherein R1 is 4-pyridyl or 3-pyridyl. R2 is hydrogen or 
methyl and R3 is 3.4-dichloro, p-or m-chloro, p-bromo. 
p-?uoro, p-lower alkyl. p-lower alkoxy or hydrogen. 
Also provided by this invention are orally active, nontoxic 
anticonvulsant compositions comprising as the active 
ingredient, a compound selected from those of the following 
formulae: 
wherein R1 is 4-pyridyl or 3-pyridyl. R2 is hydrogen or 
methyl and R3 is 3.4-dichloro. p- or m-chloro. p-bromo, 
p-?uoro, p-lower alkyl, p-lower alkoxy or hydrogen. 
Also provided are methods for administration of the 
anticonvulsant compositions of this invention to mammals 
5 ,648,369 
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including animals and humans in the treatment of convulsive 
disorders such as epilepsy including partial and generalized 
seizures. 
BRIEF DESCRIPTION OF THE DRAWING 
Reference is now made to the drawing accompanying the 
application which is a graph showing the inhibitory eifect of 
the aminoalkylpyridines of the invention on endogenous 
glutamate release. 
DESCRIPTION OF PREFERRED 
EMBODIMENTS 
As indicated above, this invention relates to several new 
compounds belonging to two groups of 
aminoalkylpyridines, which are useful as antiepileptic 
agents. One group of aminoalkylpyridines of this invention 
are l-anilino-l-pyridylethans when R2 is methyl, and the 
second group of aminoalkylpyridines are l-anilino-l 
pyridylmethans when R2 is hydrogen. The aminoalkylpy 
ridines of this invention are substituted in the l-position of 
the alkyl moiety by a 4-pyridyl or 3-pyridyl group and also 
by an anilino group (aminophenyl group) and this in turn 
also contains substituents. The alkyl moiety comprises a 
one-carbon methyl or two-carbon ethyl group. The ami 
noalkylpyridine compounds of this invention have potent 
oral anticonvulsant activity as antiepileptic drugs in the 
treatment of convulsive disorders such as epilepsy including 
partial seizures and generalized seizures. 
In one aspect of the present invention, two groups of 
compounds are provided which have potent oral antiepti 
leptic activity and which are of the following general 
formulae: 
HH 
R2 
In the above formulae, R2 is hydrogen or methyl and leads 
to the two groups of arninoalkylpyridines. When R2 is 
hydrogen, R1 is 4-pyridyl and R3 is 3.4-dichloro, p- or 
m-chloro, p-bromo, p-?uoro, p-methyl, p-methoxy, or 
hydrogen. When R2 is methyl, R1 can be 4-pyridyl or 
3-pyridyl and R3 can be 3,4-dichloro, p- or m-chloro, 
p-bromo, p-?uoro, p-methyl, p-methoxy, or hydrogen. 
Those compounds wherein R1 is 4—pyridyl, R2 is methyl or 
hydrogen and R3 is 3,4-dichloro, p- or m-chloro, p-bromo, 
p-?uoro, p-methyl, p-methoxy or hydrogen are new and 
novel compounds. 
In a second aspect of the invention, there are provided 
novel anticonvulsant compositions which are orally active 
and nontoxic, and which comprise as the active ingredient an 
eifective amount of a compound selected from those of the 
following formulae: 
HH R3 
wherein R1 is 4-pyridyl or 3-pyridyl, R2 is hydrogen or 
methyl and R3 is 3,4—dichloro, p- or m-chloro, p-bromo, 
p-?uoro, p-methyl, p-methoxy. or hydrogen. 
There are further provided by this invention methods for 
administration of the anticonvulsant composition to mam 
mals including animals and humans. 
10 
20 
25 
30 
35 
45 
50 
55 
65 
4 
In a third aspect of this invention, there are provided 
aminoalkylpyridine compounds of the formulae: 
wherein R1 is 4-pyn'dyl or 3-py1idyl, R2 is hydrogen or 
methyl, and R3 is 3,4-dichloro, p-chloro, m-chloro, p-bromo, 
p-?uoro or hydrogen. These compounds selectively inhibit 
the speci?c binding of [3H]DtI‘G to the <5 (sigma) receptor 
sites on the NMDA receptor complex and also impair the 
release of L-glutamate, the excitatory amino acid neu 
rotransmitter. Thus, new aminoalkylpyridine compounds of 
the above formulae are noncompetitive NMDA antagonists 
and 0 receptor blockers (Choi, Cerebrovas. Brain Metab. 
Revs. 2, 105-147, 1990). These aminoalkylpyridine com 
pounds of the above formulae are also useful in the treatment 
of stroke and Alzheimer’s disease, by virtue of the action of 
the above aminoalkylpyridines as inhibitors of L-glutamate 
release and as noncompetitive NMDA antagonists. 
Studies by the Applicant on the metabolism and pharma 
cology of triazoline anticonvulsants, led to the evolution and 
discovery of the aminoalkyl heterocycles as a unique class 
of anticonvulsant agents, superior to the triazolines them 
selves. [P. K. Kadaba, US. Pat. Nos. 4,511,572; 4,618,681; 
4,689,334; 4,610,994; 4,820,721]. Work on the aminoalky 
lpyridines indicate they are nontoxic, and highly effective by 
the oral route, with protective indices greater than 20. They 
impair presynaptic release of L-glutamate and also function 
as noncompetitive NMDA (N-methyl-D-aspartate) antago 
nists that inhibit with great selectivity and speci?city, the 
sigma receptor, but show no af?nity for PCP receptors. 
NMDA receptor overstimulation by glutamate is implicated 
in epileptogenesis and epilepsy. Thus, NMDA antagonists 
also provide prophylaxis and seizure protection. There is a 
de?nite need for safer, orally active NMDA antagonists, to 
afford effective therapies for the epilepsies. Excessive levels 
of glutamate are suspected not only in epilepsy, but in 
several other neurological disorders, eg. stroke. 'Ihus, 
nontoxic, orally active NMDA antagonists developed from 
aminoalkyl heterocycles, have good potential for commer 
cial application as clinically useful antiepileptic drugs and 
also as neuroprotective agents in other neurological disor 
ders. 
This invention relates to novel, new and previously 
unknown (5 (sigma) selective aminoalkylpyridines, as a 
unique class of noncompetitive NMDAreceptor antagonists, 
their methods of preparation, and compositions for their use 
as a novel class of antiepileptic drugs in the treatment of 
convulsive disorders such as epilepsy including partial and 
generalized seizures. 
Considerable evidence has accrued in the last decade and 
a half implicating amino acids in chemical neurotransmis 
sion; while GABA (gamma-aminobutyric acid) and glycine 
serve as inhibitory neurotransmitters, L-glutarnate and 
L-aspartate function as excitatory neurotransmitters in the 
central nervous system [Foster. A. C. and Fagg, G. E. Brain 
Res. Rev. 7, 103 (1984)]. There exist considerable data that 
suggest excitatory amino acids (EAAs) may be critically 
involved in both epileptogenesis and as a focus for 1116 
mechanism of action of anticonvulsants (Meldrum, B. S., 
and Chapman, A. G., In “Glutamine, Glutamate, and GABA 
in the Central Nervous System,” L. Hertz, et. al., Ed., Alan 
R. Liss, Inc., New York 1983, pp. 625-641; R. Schwarcz and 
Yehezkel-Ben-Ari, Eds. “Excitatory Amino Acids and 
5,648,369 
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Epilepsy”, Plenum Press. New York, 1986). Because brain 
function in the normal state is a dynamic balance of exci 
tatory and inhibitory processes, one would think that exces 
sive neuronal activity leading to seizures may result from 
either an increase in excitatory transmission. or, alternately, 
from a decrease in inhibitory transmission. Thus, effecting 
changes in the concentrations of either excitatory or inhibi 
tory neurotransmitters at their synapses would represent 
potential mechanisms of anticonvulsant action and strategies 
for anticonvulsant drug design. 
Strong evidence exists for the prominent role of EAAs in 
excitatory transmission along limbic circuits which are 
believed to be particularly relevant to kindling epileptoge 
nesis. More recently, evidence for a causal connection 
between EAA release and onset of hyperactivity has been 
provided by the use of speci?c EAA receptor antagonists in 
various models of epilepsy [Watkins. J. C.. and Evans, R. H. 
Ann. Rev. Pharmacol. ToxicoL, 21, 165 (1981)]. There is 
mounting evidence that the excitatory neurotransmitters, 
L-glutamate and L-aspartate, play a key role in the spread of 
epileptic activity from one brain region to another and may 
also be contributing to its initiation (Meldrum. B. S., In 
“Handbook of Experimental Pharmacology: Antiepileptic 
Drugs.” H. H. Frey and D. Janz Ed, Berlin. 1984). EAA 
agonists are convulsants and EAA antagonists show anti 
convulsant activity in a variety of seizure models. 
EAA Neurotransmitter Systems and the NMDA Receptor 
Ionophore Complex. Recent attention has focused on the 
role of EAAs and the NMDA receptor in health and disease. 
[Cavalheiro, E. A.. Lehmann. J.. and Turski. L. Eds.. “Fron 
tiers in Excitatory Amino Acid Research”, A. R. Liss, New 
York. N.Y.. 1988; Cotrnan, C. W.. et al., J. NIH Res., 1, 65 
(1989); Dingledine, R. et al., CRC Crit. Rev. NeurobioL, 4, 
1 (1988); Johnson. G.. Ann. Rep. Med. Chem, 24, 41 
(1989)]. The postsynaptic actions of L-glutarnate are 
believed to be mediated by at least three receptor subtypes 
named after the prototypical agonists N-methyl-D-aspartate 
(NMDA). kainate (KA) and quisqualate (QA). Although 
NMDA itself is not present in the brain. endogenous 
L-glutarnate has the highest a?inity for the NMDA receptor. 
The NMDA receptor is the best characterized of the three 
EAA receptor subtypes. A group of unusual characteristics 
sets the NMDA receptor apart from other glutamate 
receptors, among them, a high Ca2+ conductance, a slow 
onset of the response. and. most important. a voltage 
dependent Mg2+ blockade of the ionic channel gated by the 
NMDA receptor. Furthermore. NMDA receptors are asso 
ciated with. and in?uenced by, three additional types of 
binding sites. a PCP (the anesthetic and psychotomimetic 
drug phencyclidine) binding site that is located within the 
receptor-associated ion channel. thereby blocking channel 
conductance. a strychnine-insensitive glycine binding site 
that is distinct from the inhibitory glycine receptor of the 
spinal cord and a polyarnine recognition site [Williams K., 
Romano. C., and Molinoff, P. R., Mal. PhamuzeoL, 36. 575 
(1989)]. Several convincing arguments exist to support the 
concept that PCP receptors may constitute three subreceptor 
sites. MK-80l. PCP and 0' sites, each with a high degree of 
selectivity and speci?city to the respective ligands, MK-80l. 
TCP (a PCP analogue with a thienyl group in place of the 
phenyl) and DTG. 
NMDA receptor overstimulation by high levels of 
L-glutamate has been implicated in epileptogenesis and 
epilepsy. NMDA receptor antagonists that block the action 
of L-glutarnate, and thus the overstimulation of the NMDA 
receptor. may represent novel antiepileptic agents that can 
a?ord both prophylaxis as well as seizure protection. NMDA 
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receptor antagonists can be separated into two major groups, 
competitive and noncompetitive. The competitive NMDA 
antagonists are usually long chain amino acids of low lipid 
solubility and poor blood brain barrier penetration and 
compete for binding at glutamate recognition sites on the 
NMDA receptor complex [Honore. T.. Med. Res. Rev., 9. 1 
(1989)]. The noncompetitive NMDA antagonists. on the 
other hand. comprise a variety of different lipid soluble 
structures that include ketamine, phencyclidine. benzomor 
phan “(s opiates” and MK-801. These compounds associate 
with the PCP site within the NMDA receptor activated 
membrane channel and thus impede cation Ca2+ ?ow 
through the channel [Choi. D. W., Cerebrovas. Brain Metab. 
Revs., 2, 105-147 (1990)]. Thus, by de?nition. the sigma 
selective aminoalkylpyridines may function as noncompeti 
tive NMDA antagonists. 
The aminoalkylpyridines constitute a unique class of 
triazoline metabolite analogues; unlike the hydrophilic 
B-amino alcohol/ot-amino acid metabolites of tiiazolines, 
these hydrophobic metabolite analogues are potent orally 
active anticonvulsant agents. Furthermore. neurochernieal 
studies indicate that the ability of the ?-amino alcohol to 
interact with the NMDA receptor and that of the triazoline 
structure to impair presynaptic release of L-glutamate. are 
both retained to the full extent or better in the aminoalky 
lpyridines. Receptor binding studies indicate that while the 
general site of activity of the aminoalkylpyridines is still 
con?ned to the PCP receptor sites, the speci?city and 
selectivity. unlike that of the [i-amino alcohol. are no longer 
at the MK-801 sites. but shifted toward the 0' receptor sites 
of the PCP receptors. 
The compounds of the present invention are useful in 
pharmaceutical compositions using conventional pharma 
ceutical carriers or vehicles for administration to humans 
and animals in unit dosage forms. such as tablets. capsules, 
pills, powders. granules. suppositories, sterile parenteral 
solutions or suspensions. sterile non-parenteral solutions or 
suspensions, oral solutions or suspensions, oil in water or 
water in oil emulsions and the like. containing suitable 
quantities of the active ingredient. 
The arninoalkylpyridines of this invention may be pre 
pared by reaction of pyridine aldehydes. when R2 is 
hydrogen. or acyl pyridines. when R2 is methyl. ethyl or 
phenyl. with anilines and reduction of the resulting novel 
intermediate irnines with sodium borohydride as shown in 
Equation 1. 
In the above equation. R1. R2 and R3 are as de?ned above. 
In the method of preparation, the reaction between the 
pyridine aldehydes or ketones and anilines is carried out by 
condensing the appropriate aniline and pyridine aldehyde or 
ketone, in an organic solvent such as an aromatic hydrocar 
bon which can be benzene, toluene and xylene. The reaction 
is conducted at an elevated temperature ranging from about 
5,648,369 
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50° C. to the boiling point of the solvent used optionally 
under pressure. Preferably the reaction is conducted in the 
presence of a catalyst such as an aluminosilicate catalyst 
including commercially available molecular sieves. 
After formation of the imine by this reaction, the reduc 
tion to the aminoalkylpyridines is carried out preferably 
using an alcoholic solvent and a reducing agent such as 
sodium borohydride. The reaction is conducted with agita 
tion at a temperature of from 60° C. up to the boiling point 
of the solvent used. The product is then recovered as a solid. 
The following examples are presented to illustrate the 
invention, but it is not to be considered as limited thereto. In 
the examples and throughout the speci?cation, parts are by 
weight unless otherwise indicated. 
EXAMPLE 1 
Preparation of 1-(anilino)-1-(pyridyl)-ethans (1 
anilino-l-ethylpyridines) 
(a) Preparation of the imines: 
A mixture of the appropriate acetylpyridine (0.06 mol) 
and aniline (0.06 mol) in xylene (150 ml) was re?uxed for 
4 hours in the presence of molecular sieves (75 g) (Davison, 
grade 514, effective pore size 4A, 8-12 mesh beads). At the 
end of the reaction, the molecular sieves were ?ltered, 
washed with benzene and the combined ?ltrates rotary 
evaporated to remove xylene. The syrupy residual material 
was crystallized from benzene or benzene-petroleum ether 
mixture to yield the pure irnines in yields varying from 40% 
to 60% 
The imines that were prepared according to the above 
described procedure are given in Table 1 along with their 
melting points. 
(b) Sodium borohydride reduction of imines. To a solution 
of the imine (0.03 mol) in ethanol (100 ml) was added 
?nely powdered sodium borohydride (0.15 mol) and the 
reaction mixture re?uxed with magnetic stirring for 2-4 
hours. 
The reaction mixture was then cooled in ice and the 
excess sodium borohydride was destroyed by slow addition 
of dilute hydrochloric acid (1:1 mixture), until the reaction 
mixture was acidic and no more hydrogen evolution was 
noticed. The white inorganic solids that precipitated were 
dissolved by addition of water and the solution made basic 
to sodium hydroxide. It was then cooled in the refrigerator 
for 1-2 days, when the l-anilino-l-ethylpyridines appeared 
as white to beige colored solids. They were ?ltered, washed 
well with water, and recrystallized from acetone-petroleum 
ether mixture or te111'ary-butyl methyl ether and petroleum 
ether mixture. In Table 2, melting points and yields are given 
for all the new l-(anilino)-l-(pyridyl)-ethan compounds 
prepared. 
EXAMPLE 2 
Preparation of 1-(anilino)-1-(py1idyl)-methans 
(anilino methylpyridines) 
(a) Preparation of the imines. A mixture of the pyridine 
aldehyde (0.05 mol) and aniline (0.05 mol) in ethanol was 
heated on a steam bath, when the irnine appeared as a 
solid mass which was crystallized from ethanol-water 
mixture. [Kadaba, P. K., J. Heterocycl. Chem, 12, 143 
(1975)]. 
(b) Sodium borohydride reduction of the above imines was 
carried out according to the procedure described for the 
preparation of the l-anilino-l-ethylpyridines. 
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TABLE 1 
Melting point, 
Imine Prepared “C. 
(1) from 3,4-dichloroaniline 102-104 
and 4-acetylpyridine 
(2) from 4-chloroaniline 162-165 
and 4-acetylpyridine 
(3) from 3-chloroaniline 80-825 
and 4-acetylpyridine 
(4) from 4-bromoaniline 157-1595 
and 4-acetylpy1idine 
(5) from 4-?uoroaniline 133-135 
and 4-acetylpyridine 
(6) from p-toluidine 80-82 
and 4-acetylpyridine 
(7) from p-anisidine 111-113 
and 4-acetylpyridine 
(8) from aniline 81-845 
and 4-acetylpyridine 
(9) ?om 4-chloroani1inc 72-74 
and 3-acetylpyridine 
TABLE 2 
Melting 
Compound Point, uC. Yield, % 
(1) 1-(3,4-Diclomanilino)-l- 153-1555 68 (4-Py1'idYD-ethm1 
(2) 1-(4-Chloroanilino)-l- 104-106 79 (4-Py1‘idY1Hth?n 
(3) 1-(3-Chloroanilino)-1- 156-158 80 (4-PY1‘idyD-eman 
(4) 1-(4-Bromoanilino)-1- 107-108 34 (4-pyridyliethan 
(5) l-(4-Fluoroanilino)-1- 85-87 60 (4-Pyridy1Hthan 
(6) 1-(4-Methylanilino)-1- 93-955 72 
(4-Py1‘1dyl)-¢than 
(7) 1-(4-Methoxyani1ino)-l- 74.5-76 70 
(4-Py?dy1>¢m 
(8) 1-(Anilino)-l-(4-pyridyl)- 126-128 60 
ethan 
(9) 1-(4-Chloroanilino)-1- 121-123 63 (3-pyridylletban 
(10) 1-(3,4-Dichloroanilino)-1- 99-1015 31 
(4-pyridyl)-methan 
(11) 1-(4-Chloroanilino)-1- 91-94 26 (4-pyn'dyl)-methan 
(12) 1-(3-Chloroanilino)-1- 82-84 18 (4-pyridyl)-methan 
(13) 1-(4-Bromoanilino)-1- 92-945 32 (4-pyridyl)-methan 
(l4) 1-(4-Flmroanilino-1- 67-70 33 
(4-pyridyl)-methan 
(15) l-(4-Methylanilino)-1- 71-73 38 
(4-pyridyl)-methan 
(16) 1-(4-Methoxyanilino)-1- 74.5-76 33 
(4-pyridyl)-methan 
The compounds in Table 1 and Table 2 were identi?ed 
through their elemental analyses, melting points, and NMR 
spectra (for Table 2 compounds) which show a characteristic 
doublet of a quartet for the CH proton, when R2 is methyl 
and a simple doublet of the CH2 group when R2 is hydrogen, 
in the 4.3-4.5 5 region. 
EXAMPLE 3 
The aminoalkylpyridine compounds and the resulting 
orally e?’ective anticonvulsant compositions of this inven 
tion are useful in the treatment of convulsive disorders. The 
oral potency of the compounds range from those which are 
very highly potent to those of good medium potency, with no 
accompanying toxicity. A series of aminoalkylpyridines of 
5,648,369 
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this invention has been evaluated for anticonvulsant activity 
by the intraperitoneal (i.p.) and by the oral (p.o.) route using 
two standard seizure models in the mouse and in the rat, the 
maximal electroshock seizure (MES) test and the subcuta 
neous pentylenetetrazol (Metrazole) seizure threshold 
(scMet) test. These two methods of seizure provocation 
reliably elicit well characterized seizure phenomena and 
together they have been shown su?icient to identify all 
compounds known to demonstrate anticonvulsant activity in 
other tests [Porter, R. J ., et al., Cleveland Clinic Quarterly. 
51. 293 (1984)]. Based on the screening results. the com 
pounds are placed in one of three categories. Those failing 
to demonstrate anticonvulsant activity at doses up to 300 
mg/kg are considered inactive. Class II compounds show 
anticonvulsant activity at doses greater than 100 mgkg or 
show activity at 100 mg/kg which is not reinforced by 
similar activity at 300 mg/kg. Thus, compounds of class or 
group 11 demonstrate anticonvulsant activity without signs 
of neurological de?cit, but do not have signi?cant potency. 
The Class I compounds are those which are most promising 
as anticonvulsants. They demonstrate anticonvulsant activ 
ity in either the MES test or the scMet test, or both at doses 
of 100 mg/kg or 30 mg/kg without signs of neurological 
de?cit and this have an estimated protective index of greater 
than 1. 
Neurotoxicity is determined by the rotorod ataxia test in 
mice and by the positional sense test and gait and stance test 
in the rat. 
The following Table 3 presents the results of these anti 
convulsant tests with respect to several compounds of the 
present invention. This Table 3 identi?es the speci?c com 
pounds tested by chemical name and provides the route of 
administration, the animal species used, and the anticonvul 
sant activity based on classi?cation in Group I or Group II. 
when intraperitoneally administered, and based on percent 
protection. when orally administered. 
As shown in Table 3. all the aminoalkylpyridine com 
pounds belong to Class I and demonstrate anticonvulsant 
activity at doses of 30 mg/kg to 100 mg/kg. without signs of 
neurological de?cit. The anticonvulsant activity of the com 
pounds is far more pronounced in the MES test than in the 
scMet test. in both mice and rats. by the i.p. and oral routes 
of administration. and protective indices greater than 20 are 
obtained by oral administration in the rat. 
Anticonvulsant quanti?cation in mice. i.p.. for 6 com 
pounds (Table 4) further con?rms the greater potency of the 
aminoalkylpyridines in the MES test; in the scMet test, 
protection is obtained only at high dose levels nearing toxic 
doses. Anticonvulsant quanti?cation in rats, p.o. (Table 5) 
clearly shows that the aminoalkylpyridines, as a class. are 
inelfective in the scMet test, but evince a remarkably high 
degree of anticonvulsant activity by the oral route in the 
MES seizure model, with R1. values >20. 
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The potent activity of the aminoalkylpyridines in the MES 
test is of great signi?cance, because drugs used in the 
treatment of the two major types of seizures (partial and 
generalized) are quite distinct in their clinical effects. They 
also fall into two pharmacological classes even though 
seizures may be induced experimentally by a wide variety of 
methods. The clinical aspects of certain generalized 
seizures. especially absence seizures, are highly correlated 
with experimental seizures produced in the scMet model. 
Likewise, partial seizures in humans correlate positively 
with experimental seizures elicited by the MES test (Porter. 
R. J.. and Pitlick. W. H., In “Basic and Clinical 
Pharmacology”, 4th Ed.. B. G. Katzung Ed., Appleton & 
Lange. C. A.. 1989. pp. 287-303). 
TABLE 3 
Percent 
ASP Group protection* 
Classi?- at 50 rug/kg dose, 
cation p.o., in the MES 
Compound (i.p. mouse) Test in the rat 
(1) l-(3,4-Dic1oroanilino)-l- I — 
(4-pyrldyl)~ethan 
(2) l-(4-Cloroanilino)-l- I 75-100 
(4-pyridyl)-ethan 
(3) l-(3-Chloroanilino)-1- I 50-75 
(4-pyridyl)-ethan 
(4) l-(4-Bromoani1ino)-l- I 75-100 
(4-pyridyl)-ethan 
(5) 1-(4-Flmroanilino)-1- I 75-100 
(4-pyridyl)-ethan 
(6) l-(4-Methylanilino)-1- I —— 
(4-Pyridy1)*¢m 
(7) l-(4-Methoxyanilino)-1- I 25-50 
(4~pyridyl)-ethan 
(s) 1-(Anilino)-1- 1 50-75 
(4-pyridyl)-ethan 
(9) 1-(4-Chloroanilino)-l- I 25-75 
(3-pyridyl)-ethan 
(10) 1-(3,4-Dichloroanilino-1- I 50 
(4-pyridyl)-methan 
(l1) 1-(4-Chloroanilino)-1- I 50-100 
(4-pyridyl)-methan 
(12) 1-(3-Chloroani1ino)-1- I >50 
(4-pyridyl)-methan 
(13) l-(4-Bromoanilino)-l- I >50 
(4-pyridyl)-metl1an 
(14) l-(4-F1uoroani1ino-l- I 25 
(4-pyridyl)-metl1an 
(15) 1-(4-Methylanilino)-1- I — 
(4-pyridy1)-rnethan 
(16) 1-(4-Methoxyanilino)-l- I - 
(4-pyridyl)-methan 
*Number of animals protected/number of animals tested is de?ned as percent 
protection. 
TABLE 4 
Anticonvulsant Quanti?cation in Mice. i.p. 
TDso 
Time of EDSD, mgilig rug/kg RI.“1 
Compound Test (11)a MES ScMet (rotorod) MES 
(2) l-(4-Chloroanilino)-l- 0.25, 0.25 53.71 <150 160.11 2.98 
(4-pyridyl)-ethan 0.25 (51.61-57.34)“ (130.8’7-18759) 
[31.40 i‘ 9.80]° [9.81 i 2.95] 
(a) 1-(3-Chloroanilino)-1- 1, 1 95.45 >250 >500 >524 
5,648,369 
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TABLE 4-continued 
12 
Anticonvulsant Qugti?cation in Mice, ip. 
T1350 
Tme of ED“. m?g mg/kg P1.d 
Compolmd Test (h)a MES ScMet (rotorod) MES 
(4-pyn'dyl)-ethan 24 (7199-1133) 
[8.50 i 296] 
(4) l-(4-Bromoanilino)-l- 4, 4 62.74 >200 >200 >3.19 
(4-pyridyl)-ethan 0.25 (50.60-80.48) 
[5.42 i 1.56] 
(5) 1-(4-Fluoroanilinol)-1- 0.25, 0.5 57.42 >80 141.1 2.46 
(4-pyridyl)-ethan 0.25 (50.94-66.55) (117.5-171.9) 
[12.36 i 3.67] [9.55 i 
3.04] (8) l-(Anilin0)-l- 0.5, 0.5 81.74 <i00 161.0 1.97 
4-pyridyl)-ethan 0.25 (72.94-96.81) (125.8-1949) 
[11.17 i 3.55] [6.84 i 
2.05] (11) l-(4-ChloroanilinO)-1- 0.5, 0.5 68.43 106.9 <225 6.3 
(4-pyridy1)-methan 0.25 (63.16-76.43) (80.28—140.10) 
[20.43 i 6.81] [6.07 i- 1.58] 
"Tune of test is given in the order for MES, scMet, and rotorod 
b( ) 95% con?dence interval 
°[ ] Slope, regression line i standard error 
"P1. = TDSOIED5o 
TABLE 5 
Anticonvulsant {@tj?cation in Rat, 2.0. 
Time 
of TDso 
Test EDS“, mg/_1_<g mg] Pr.‘l 
Compound (h)" MES ScMet kg MES 
(2) 1-(4-Chloro- 2, 2, 22.89 >250 >470 >20.53 
minim-1- 0.25 (14.40-32.70)b 
(4-pyridyl)- thru [3.17 i 1.19]° 
ethan 24 
(4) 1-(4-Bromo- 4, 4, 20.89 >250 >500 >23.93 
anilino1)-1- 1 (16.76-26.13) 
(4-pyridyl)- [6.88 i 2.43] 
ethan 
(5) 1-(4-F1uoro- 0.5, 81.06 >250 >500 >6.17 
ani1ino)-l- 0.5, (53.82-1325) 
(4-pyridy1)- 0.25 [2.94 i 0.99] 
ethan thru 
24 
(8)1-(Anilino)- 0.5, 48.40 >250 >500 >10.33 
1-(4- 0.5, (33.12-77.60) 
pyridy1)- 0.25 [3.61 i 1.23] 
ethan thru 
24 
(11) l-(4-Chloro- 4, 4, 39.14 >250 >500 >12.8 
a11111J10)-1- 0.25 (24.30-58.65) 
(4-pyridy1)- thru [2.85 i 0.74] 
methane 24 
'Iime of test given in the order for MES, scMet, and rotorod 
b( ) 95% con?dence interval 
c[ ] Slope, regression line 1 standard error 
The anticonvulsant compounds of the present invention 
may be administered to animals or humans at doses ranging 
from about 15 mg/kg up to about 200 mg/kg. Preferred 
levels of administration range from about 15 mg/kg up to 
100 mg/kg. The active ingredients or compounds of this 
invention may be administered in any desired form by 
injection or in the oral form. Conventional adjuvents and 
carriers may be employed in combination With about 0.001 
to 2.0 wt. % of the active ingredient. Thus, the anticonvul 
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sant compositions of this invention may be administered in 
pill form or by injection. As indicated above, the dosage rate 
ranges from about 15 mg/kg up to about 200 mg/kg. 
Screening Methodology to Determine Anticonvulsant 
Activity: In mice, i.p.: All compounds are solubilized in 
0.5% methylcellulose. The solvent has been tested for anti 
convulsant and toxic eifects and found to introduce no 
signi?cant bias into the testing of anticonvulsant activity. 
The compounds are administered intraperitoneally in a vol 
ume of 0.01 ml/gm to male CarWorth Farms #1 mice 
weighing about 20 gm. All compounds are tested at least at 
three dose levels (30, 100 an 300 mglkg) at 30 minutes and 
4 hours after their administration. 
The Maximal Electroshock Seizure Test (MES): Maximal 
electroshock seizures are elicited with a 60 Hz alternating 
current of 50 mA intensity in mice and about 150 mA in rats 
(5-7 times that necessary to elicit minimal electroshock 
seizures), delivered for 0.2 sec via corneal electrodes. A drop 
of 0.9% saline is instilled in the eye prior to application of 
the electrodes in order to prevent the death of the animal. 
Abolition of the hind limb tonic extension component of the 
seizure is de?ned as protection and results are expressed as 
number of animals protected/number of animals tested. 
The Subcutaneous Pentylenetetrazol (Metrazole) Seizure 
Threshold Test (scMet): A 0.5% solution of 85 mg/kg of 
pentylenetelrazol is administered subcutaneously in the pos 
terior midline. The animal is observed for 30 minutes. 
Failure to observe even a threshold seizure (a single episode 
of clonic spasms of at least 5 sec duration) is de?ned as 
protection and the results are expressed as number of 
animals protected/number of animals tested. 
Neurotoxicity is evaluated in mice by the rotorod ataxia 
test The animal is placed on a Wooden rod of 1V8" diameter 
rotating at 6 rpm. Normal mice can remain on a rod rotating 
at this speed inde?nitely. Neurologic toxicity is de?ned as 
the failure of the animal to remain on the rod for 1 minute 
and is expressed as number of animals exhibiting toxicity/ 
number of animals tested. 
Anticonvulsant Quanti?cation in Mice, i.p.: The EDS0 
values are determined in the MES, scMet and rotorod ataxia 
5,648,369 
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test. To determine the ED50 values, ?ve logarithmically 
spaced doses of the test compound are administered to 
animals in groups of ten, to cover 0-100% protection, and 
the dose required to protect 50% of the animals (EDSO) 
together with its 95% con?dence limits, are determined 
graphically. 
Anticonvulsant Quanti?cation in Rats p.o.: Substances 
which exhibit unusual potential as possible antieptileptic 
drugs, as determined from all prior testing will be subjected 
to anticonvulsant activity test in the rat (Sprague-Dawley 
strain). This species will be subject of the complete anti 
convulsant quanti?cation test evaluation as described above. 
but after oral (gavage) administration of the candidate 
compound. These results will permit the critical comparison 
of the anticonvulsant activity and neurotoxicity of the agent 
under study with similar data previously obtained in mice. 
Substances which exhibit potential antiepileptic activity will 
be advanced for toxicity and selected pharmacology studies. 
Neurological de?cit in rats is examined by the positional 
sense test and gait and stance test. In the positional sense 
test, one hind leg is gently lowered over the edge of a table, 
whereupon the animal will quickly lift it back to normal 
position. Inability to do so rapidly indicates a neurologic 
de?cit. In the gait and stance test, a neurologic de?cit is 
indicated by a circular or zigzag gait. ataxia. abnormal 
spread of the legs, abnormal body posture. tremor, 
hyperactivity, lack of exploratory behavior, somnolence, 
stupor, or catalepsy. 
EXAMPLE 4 
EAAs are lmown to play important roles in excitatory 
neurotransmission in partial seizures as discussed earlier. 
Evaluation of potential displacement activity of aminoalky 
lpyridine compounds 1, 2, 3, 4, 5, 6, 8. 9. 10. 11. 12 and 13 
at all inhibitory and excitatory amino acid receptor types and 
subtypes using appropriate radioligands, according to 
known procedures indicated that aminoalkylpyridines 
inhibit selectively the binding of [3H]DTG, a ligand highly 
speci?c for the o (sigma) receptor population of the PCP 
receptors on the NMDA receptor-ionophore complex 
(Weber et al., Proc. Nat. Acad. Sci.. 83, 8784 (1986)]. They 
show no activity at the [3HlMK-801- or [3H]TCP-binding 
receptor sites of the PCP receptor. The aminoalkylpyridines 
also inhibit Ca2+ dependent. K‘“ evoked release of endog 
enous L-glutamate in guinea pig cerebrocortical slices. 
Thus. several aminoalkylpyridines of this invention are 
effective antagonists of NMDA-receptor mediated EAA 
neurotransmission and function as noncompetitive NMDA 
antagonists and thus can be used to advantage in epilepsy. 
stroke and Alzheimer’s disease. 
Aminoalkylpyridines Attenuate EAA Neurotransmission: 
Role as Noncompetitive NMDA Antagonists: There are 
several approaches to antagonizing glutamate-mediated 
excitatory processes. and glutamate neurotoxicity. Based on 
Choi’s speculative consideration of glutamate neurotoxicity 
as a sequential three-stage process—induction, ampli?ca 
tion and expression—a range of measures might be used to 
protect neurons from excitotoxic damage. since each step of 
the neurotoxic process is speci?cally amenable to therapeu 
tic interference [Choi, D. W., Cerebrovas. Brain Metab. 
Revs., 2. 105-147 (1990)]. Blockade of induction. i.e. 
overstimulation of glutamate receptors inducing intracellu 
lar accumulation of cazl'. might be accomplished most easily 
by antagonizing postsynaptic glutamate receptors, as also by 
reducing glutamate release from presynaptic terminals. 
EAAs are known to play important roles in excitatory 
transmission in partial seizures as discussed earlier. In 
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general. antieptileptic drugs effective against MES seizures 
alter ionic transport across excitable membranes [Porten R. 
J ., and Pitlick. W. H., In “Basic and Clinical Pharmacology”, 
4th Edn., B. G. Katzung, Ed.. Appleton and Lange. CA 1989. 
pp. 287-303]. Based on this rationale, the aminoalkylpy 
ridines may be expected to attenuate EAA neurotransmis 
sion. Indeed, evaluation of potential displacement activity of 
#2 at all inhibitory and excitatory amino acid receptor types 
and subtypes using appropriate radioligands, indicate that 
this arninoalkylpyridine inhibits at 10 1.1M concentration. 
49% of the binding of [3H]DTG, a ligand highly speci?c for 
the <5 (sigma) receptor population of the PCP receptors on 
the NMDA receptor-ionophore complex (Table 6). It shows 
no activity at the [3H]MK-8O1- or [sHlTCP-binding receptor 
sites of the PCP receptor. The aminoalkylpyridine (#2) also 
inhibits Ca2+ dependent, K+ evoked release of endogenous 
L-glutamate in guinea pig cerebrocortical slices to an extent 
of 74% at 50 M and 80% at 100 pM concentrations, 
comparable to the parent ADD17014 (Table 6). Because 
aminoalkylpyridines in general are highly effective in the 
MES seizure model, these compounds. as a class can be 
expected to be effective antagonists of NMDA-receptor 
mediated EAA neurotransrnission. The ability of the ami 
noalkylpyridines to selectively inhibit the 0 receptor sites, in 
addition to impairing presynaptic release of L-glutamate. 
offers potential for their use as noncompetitive NMDA 
antagonists to afford protection against epilepsy, 
particularly, partial seizures including complex partial sei 
zures where there is a de?nite need for more effective drugs, 
as discussed earlier. 
The Therapeutic Potential of Aminoalkylpyridines as 
Clinically Useful Antiepileptic Drugs: Potent Orally Active. 
Nonneurotoxic Anticonvulsant Agents: The aminoalkylpy 
ridines have evolved as a result of studies on the metabolism 
and pharmacology of the 1,2.3-triazoline anticonvulsants. 
They are highly lipophilic molecules that can readily cross 
the blood brain barrier. In screening experiments using 
animal seizure models. they show a high degree of anticon 
vulsant activity by the oral route with no attendant 
neurotoxicity, and with P1. values >20. When compared 
with the respective parent triazolines, the aminoalkylpy 
ridines appear to be superior anticonvulsant agents (see 
Table 8 for comparison of data). Unlike the rigid. closed ring 
structures of the triazolines and aziridines. the ?exible, open 
structures of the aminoalkylpyridines show inhibitory activ 
ity at postsynaptic NMDA receptors while also fully retain 
ing the ability of the parent to impair presynaptic release. 
TABLE 6 
Inhibition of speci?c binding of radioligands at 
EAA - recc tors b amin l-4- ‘dine #2 
Refer- Percent Inhibition 
Receptor! Radio Reference ence (Averagez N = 2) 
Selectivity ligand Compound Ki (nM) 104M 1.0_$M 
Adenosine 
Adenosine MECA 39.50 —15.2 —15.9 
Amino Acids 
Excitatory 
Glycine FHJglycine D-Alanine 4900.00 8.7 —4.0 
Kainate [3H]KA Kainic Acid 24.93 —3.7 —7.3 
NIX-801 [3HJMK-8O1 MK-SOl 4.30 13.5 17.0 
NMDA [3H]CGS 19755 CPP 359.00 3.5 —6.6 
PCP [3I-l'jTCP PCP 62.30 —3.8 —1.8 
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TABLE 6-continued TABLE 8-continued 
Inhibition of speci?c binding of radioligands at classi?cation, active classi?wl?on 
EAA - receptors by aminQlsylA-pg'dine (#2) at 300 mg/kg only) ac?ve at 100 
5 rug/kg) 
Refer- Percent Inhibition 4-OCH3 Class 11 (ASP Class I (ASP 
Receptor! Radio Reference ence Avera e' N = 2 classi?cation, I10! 25-50% 
active up to 300 mg/kg) protection at 
Selectivi ligand Compound Ki (nM) 1O"7M 1.04M so ins/kg 
ty H Class 11 (ASP 48.40 
Quisqualate [3H]AMPA AMPA 11.80 4.2 4.3 10 classi?cation, active 
Sigma [3H]DTG Haloperidal 11.50 12.9 49.1 at 300 mg/kg only) 
Inhibitory 
Benzo- Clonazepam 3.40 -4.7 -7 .8 This invention has been described herein with reference to 
dlaZePlm _ certain preferred embodiments. However, as obvious varia 
gg‘g: 18:51:13’! 17:38 2': 15 tions thereon will become apparent to those sln'lled in the art, 
Glycine Stryc] . 31 50 _1.8 _1.4 the mvennon 1s not to be considered as limited thereto. 
Nitrate What is claimed is: 
1. A compound of the following formulae: 
Values are expressed as the percent inhibition of speci?c binding and 
represent the average of duplicate tubes at each of the concentrations tested. 20 1?: ]|-[ R3 
R1 —? —N 
2 TABLE 7 R 
Inhibi?m °f L'glutamate release by ADD17O14 and 25 wherein R1 is 4-pyridyl, R2 is hydrogen or methyl and R3 is 
l-(4-chloroanilino)-l-ethyl-4-pyridine (#2) p_methyl or p_methoxyl 
E?ects of drugs: Results are shown on the attached ?gure and in the 2. A compound according to claim 1 wherein R2 is methyl 
table below. All results are means 1 SEM of n = 4 independent and R3 is p-methyl. 
exPemnents Pel'fm'med “1 'nPhcate- 3. A compound according to claim 1 wherein R2 is methyl 
Release of endogenous gluatamate in the presence of ADD17014 and #2 30 and R3 is _methoxy 
and 30 mM K", signi?cantly di?erent from e?’ects of K1’ alone p ' . . . 2 . 
(P < 0.001) 4. A compound according to claim 1 wherem R is 
Treatment Release (% basal) hydrogen and R3 is p'methyl- 2 
5. A compound according to claim 1 wherein R is 
basal 2 + 108 i 2 hydrogen and R3 is p-methoxyl. 
2311151554 184 i 10 35 6. A potent orally active, nonneurotoxic anticonvulsant 
—- composition comprising as the active ingredient, an anti 
50 PM (basal) 101i 9 convulsant eifective amount of a compound selected ?'om 
50 PM (I?) 136 i 6 the group consisting of those of the formulae: 
100 1.1M (basal) 109 i 4 
100 1.1M (14*) 122 t 5 H H R3 
Aminoalkylpyridine #2 40 l | 
1_C_ 50 M (basal) 101 i 6 R | N 
50 M (K*) 121 i 8 R2 
100 11M (basal) 99 i 9 
100 11M (16) 114 i 4 
45 wherein R1 is 4-pyridyl. R2 is hydrogen or methyl and R3 is 
p-methyl or p-methoxy, and a pharmaceutical carrier. 
7. A co osition accordin to claim 6 wherein R1 is TABLE 8 mp g 
4-pyridyl, R2 is methyl and R3 is p-rnethyl. 
Comparison of Anticonvulsant E?icacy of Triazounes with 8. A composition according to claim 6 wherein R1 is 
Aminvalkylpyridines in the MES Test, Rat. 1m 50 4-pyridyl, R2 is methyl and R3 is p-methoxy. 
9. A composition according to claim 6 wherein R1 is 
X 4-pyridyl, R2 is hydrogen and R3 is p-methyl. 
10. A composition according to claim 6 wherein R1 is 
N 0 1'“ 4-py11'dyl, R2 is hydrogen and R3 is p-methoxy. 
N 55 11. A potent orally active, nonneurotoxic anticonvulsant 
N/ composition comprising as the active ingredient, an anti 
convulsant effective amount of a compound of the formulae 
ADD17014 
Nee-Ne 6“ (‘1113 R2 
x 
wherein R1 is 4-pyridyl, R2 is methyl and R3 is p-chloro, and 
4.C1 26576 2239 65 a pharmaceutical carrier. 
4-CH3 Class 11 (ASP Class I (ASP 12. A potent orally active, nonneurotoxic anticonvulsant 
composition comprising as the active ingredient, an anti 
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convulsant effective amount of a compound of the formulae 
H H R3 
l I 
R1—(|:-N 
R2 
wherein R1 is 3-pyridyl, R2 is methyl and R3 is p-chloro, and 
a pharmaceutical carrier. 
13. A composition according to claim 6 wherein a suffi 
cient amount of the effective ingredient is contained in said 
composition to provide a dosage amount ranging from about 
15 mg/kg to 200 mg/kg. 
14. A method for the treatment of convulsive disorders in 
mammals which comprises administration thereto of an 
effective dosage amount of an anticonvulsant composition of 
claim 6. 
15. A method according to claim 14 wherein the compo 
sition is administered in a dosage amount ranging from 
about 15 mg/kg to 200 mg/kg of body weight 
16. An inhibitor of excitatory amino acid (EAA) neu 
rotransmission which comprises inhibition of L-glutamate 
release and NMDA/sigma receptor blocking, comprising an 
effective amount of a compound of the following formulae: 
HH R3 
R2 
wherein R1 is 4-pyridyl or 3-pyridyl. R2 is hydrogen or 
methyl and R3 is p-methyl or p-chloro and a pharmaceutical 
carrier. 
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17. An EAA inhibitor and noncompetitive NMDA 
antagonist/6 receptor blocker composition according to 
claim 16, wherein R1 is 4-pyridylt R2 is methyl and R3 is 
p-chloro. 
18. An EAA inhibitor and noncompetitive NMDA 
antagonist/0' receptor blocker composition according to 
claim 16, wherein R1 is 4-pyridyl, R2 is methyl and R3 is 
p-methyl. 
19. An EAA inhibitor and noncompetitive NMDA 
antagonist/o receptor blocker composition according to 
claim 16. wherein R1 is 3-pyridyl, R2 is methyl and R3 is 
p-chloro. 
20. An imine of the formula: 
R3 
wherein R1 is 4-pyridyl or 3-pyridy1. R2 is hydrogen or 
methyl. and R3 is 3.4-dichloro. p-chloro, m-chloro, p-bromo, 
p-?uoro. p-lower alkyl. p-lower alkoxy or hydrogen. 
21. An imine according to claim 20 wherein R1 is 
4-pyridyl. R2 is methyl and R3 is 3,4-dichloro, p-chloro, 
m-chloro, p-bromo, p-?uoro. p-methyl. p-methoxy or hydro 
gen. 
22. A composition according to claim 6 wherein the active 
ingredient is contained in the composition in an amount of 
0.001 to 2.0 wt. %. 
